Network robustness stands for the capability of networks in resisting failures or attacks. Many robustness measures have been proposed to evaluate the robustness of various types of networks, such as small-world and scale-free networks. However, the robustness of biological networks is different for their special structures related to the unique functionality. Cancer signaling networks which show the information transformation of cancers in molecular level always appear with robust complex structures which mean information exchange in the networks do not depend on skimp pathways in which resulting the low rate of cure, high rate of recurrence and especially, the short time in survivability caused by constantly destruction of cancer. So a network metric that shows significant changes when one node is removed, and further to correlate that metric with survival probabilities for patients who underwent cancer chemotherapy is meaningful. Therefore, in this paper, the relationship between 14 typical cancer signaling networks robustness and those cancers patient survivability are studied. Several widely used robustness measures are included, and we find that the natural connectivity, in which the redundant circles are satisfied with the need of information exchange of cancer signaling networks, is negatively correlated to cancer patient survivability. Furthermore, the top three affected nodes measured by natural connectivity are obtained and the analysis on these nodes degree, closeness centrality and betweenness centrality are followed. The result shows that the node found are important so we believe that natural connectivity will be a great help to cancer treatment.
Citation: Mingxing Zhou, Jing Liu, Shuai Wang, Shan He. A comparative study of robustness measures for cancer signaling networks[J]. Big Data and Information Analytics, 2017, 2(1): 87-96. doi: 10.3934/bdia.2017011
[1] | Robin Cohen, Alan Tsang, Krishna Vaidyanathan, Haotian Zhang . Analyzing opinion dynamics in online social networks. Big Data and Information Analytics, 2016, 1(4): 279-298. doi: 10.3934/bdia.2016011 |
[2] | Bill Huajian Yang . Modeling path-dependent state transitions by a recurrent neural network. Big Data and Information Analytics, 2022, 7(0): 1-12. doi: 10.3934/bdia.2022001 |
[3] | Yaru Cheng, Yuanjie Zheng . Frequency filtering prompt tuning for medical image semantic segmentation with missing modalities. Big Data and Information Analytics, 2024, 8(0): 109-128. doi: 10.3934/bdia.2024006 |
[4] | Xiaoxiang Guo, Zuolin Shi, Bin Li . Multivariate polynomial regression by an explainable sigma-pi neural network. Big Data and Information Analytics, 2024, 8(0): 65-79. doi: 10.3934/bdia.2024004 |
[5] | Jason Adams, Yumou Qiu, Luis Posadas, Kent Eskridge, George Graef . Phenotypic trait extraction of soybean plants using deep convolutional neural networks with transfer learning. Big Data and Information Analytics, 2021, 6(0): 26-40. doi: 10.3934/bdia.2021003 |
[6] | Cun Chen, Hui Peng . Dynamic mode decomposition for blindly separating mixed signals and decrypting encrypted images. Big Data and Information Analytics, 2024, 8(0): 1-25. doi: 10.3934/bdia.2024001 |
[7] | Enrico Capobianco . Born to be Big: data, graphs, and their entangled complexity. Big Data and Information Analytics, 2016, 1(2): 163-169. doi: 10.3934/bdia.2016002 |
[8] | Sayed Mohsin Reza, Md Al Masum Bhuiyan, Nishat Tasnim . A convolution neural network with encoder-decoder applied to the study of Bengali letters classification. Big Data and Information Analytics, 2021, 6(0): 41-55. doi: 10.3934/bdia.2021004 |
[9] | Nickson Golooba, Woldegebriel Assefa Woldegerima, Huaiping Zhu . Deep neural networks with application in predicting the spread of avian influenza through disease-informed neural networks. Big Data and Information Analytics, 2025, 9(0): 1-28. doi: 10.3934/bdia.2025001 |
[10] | David E. Bernholdt, Mark R. Cianciosa, David L. Green, Kody J.H. Law, Alexander Litvinenko, Jin M. Park . Comparing theory based and higher-order reduced models for fusion simulation data. Big Data and Information Analytics, 2018, 3(2): 41-53. doi: 10.3934/bdia.2018006 |
Network robustness stands for the capability of networks in resisting failures or attacks. Many robustness measures have been proposed to evaluate the robustness of various types of networks, such as small-world and scale-free networks. However, the robustness of biological networks is different for their special structures related to the unique functionality. Cancer signaling networks which show the information transformation of cancers in molecular level always appear with robust complex structures which mean information exchange in the networks do not depend on skimp pathways in which resulting the low rate of cure, high rate of recurrence and especially, the short time in survivability caused by constantly destruction of cancer. So a network metric that shows significant changes when one node is removed, and further to correlate that metric with survival probabilities for patients who underwent cancer chemotherapy is meaningful. Therefore, in this paper, the relationship between 14 typical cancer signaling networks robustness and those cancers patient survivability are studied. Several widely used robustness measures are included, and we find that the natural connectivity, in which the redundant circles are satisfied with the need of information exchange of cancer signaling networks, is negatively correlated to cancer patient survivability. Furthermore, the top three affected nodes measured by natural connectivity are obtained and the analysis on these nodes degree, closeness centrality and betweenness centrality are followed. The result shows that the node found are important so we believe that natural connectivity will be a great help to cancer treatment.
Network robustness describes networks performance when suffering from failures on nodes or edges. According to nowadays investigations [1,21,7,8,9,24,23,29,18,27,14], robust networks keep stable if the failures on nodes or edges are not fatal even if large numbers of nodes or edges are removed. And this situation may exist in the cancer signaling networks (CSNs), which makes these cancers difficult to cure. CSNs are constructed based on the information exchange of cancers in the molecular level [10,25,11], so the more robust a CSN is, the more difficult the cancer can be cured. Moreover, even if the cancer is cured in the situation where the CSN is not collapsed, the cancer will recrudesce with a high possibility. This is the reason why cancers are cured in low rate and recrudesce in high rate.
Robust CSNs should result a short time for patients to survival; otherwise, a longer time. As is known to all, canceration of cells happen every now and then, so cancers may not fatal at the first stage. However, once the immune system cannot clean cancercells in time, they will constantly strengthen themselves and weaken human beings body. Even if a cancer is diagnosed, an effective method to control it is of great importance; or, the cancer will quickly develop into fatal degree. Directly, the more robust a CSN is, the more difficult to control the cancer. And in this case, cancer patients will survival for a short time during which cancers quickly developed to be a fatal one; otherwise will survival longer.
Dylan Breitkreutz et al. in [6] studied the relationship between CSNs degree-entropy and cancer patient survivability, and the strong negative relationship is obtained, furthermore, then analysis the betweenness centrality of nodes in CSNs and think that the high betweenness nodes may hold the cancer to be alive. Inspired by this, Kazuhiro Takemoto et al. in [26] discussed the relationship between modular organization of CSNs and patient survivability, and they declared this relationship is more reliable than the previous one. To be intuitionally, robustness including errors and tolerance should be more useful in cure cancer.
Nowadays, many useful robustness measures have been proposed [8,9,24,23,29,18,27,14], and different robustness measures always focus on different aspects and suit for different networks such as small-world, scale-free networks. While CSN is a special kind of networks, in which protein dependents on genes and protein is renewable if gene works well, this system is born to be robust and can be fixed by itself dynamically. No matter how robust the CSN is, we hope to destroy it effectively, so a robustness measure which can properly evaluate the robustness of CSN so as to destroy it easily is meaningful.
In this paper, the relationship between CSNs robustness and cancer patient survivability is studied. The measures used to analyze the networks robustness quantified are different and focused on different aspects of networks. That is to say, not all robustness measures reflect the essence of CSNs; so several widely used robustness measures are included and only one measure is found to be useful and according to this measure, what is important to CSNs is analyzed.
The rest of this paper is organized as follows. The background information about CSNs and patient survivability is introduced in Section Ⅱ. Section Ⅲ describes the robustness measures studied. Next, the experiments and conclusion are given in Sections Ⅳ and Ⅴ, respectively.
Cancers are system diseases constructed by genes, protein, and ramification with complex interaction. Usually, the proto-oncogene is activated by radioactive rays, toxic substance or virus infection and with the accumulation of proto-oncogenes, the compounded protein and ramification from proto-oncogenes turn the normal interaction system into a lesion one, and then normal cells turn into cancer cells. Immune system can clean these cancer cells so as to keep us healthy; otherwise the cancer cell will infinitely proliferate and develop into a tumor and diffuse to the whole body.
Recent technology on curing cancer is to disable the genes, protein or ramification in the CSNs so a technological understanding of cell information exchange cycle malfunction during carcinogenesis, cancer progression, and response to treatment, is crucial for optimum drug development and proper drug administration. Each cell is a complex interaction system constructed by huge amount of molecular which are not fully understood so far. Nonetheless, some insights on how genes, protein and ramification interact with each other through reconstruction of regulation network [13,2,22] and how specific drugs interact with their molecular targets in the cell are beginning to be elucidated [20,28].
Signaling pathways or metabolic pathways are reconstructed biochemical networks which are observed from the interactions in cells. These biochemical networks basically contain the secret of life including information of cancer and potential way to cure itand should directly relate to cancer patient survivability.
Large numbers of cancer sites system has been worked out with the moderately detailed pathway, and 14 of these typical caner pathways are available from http://www.genome.jp/kegg/, the Kyoto Encyclopedia of Genes and Genomes (KEGG). The KEGG cancer pathways were downloaded as KGML files from the KEGG PATHWAY database (http://www.genome.jp/kegg/pathway.html). And generate a mathematical graph representation of the pathway through KEGGgraph package downloaded from http://www.bioconductor.org/, the Bioconductor Web site. In the KEGGgraph package, function parseKGML2Graph are used to generate two types of networks, called CSN-EG and CSN-GO respectively, with two group of parameters, "genesOnly = FALSE, expandGenes = TRUE and "genesOnly = TRUE, expandGenes= FALSE. Here, we study the undirected and un-weighted networks and the details of these networks are reported in Table 1.
Cancer site | 5-y survival probability | CSN-EG | CSN-GO | ||
Nodes | Edges | Nodes | Edges | ||
Acute myeloid leukemia | 23.6% | 57 | 152 | 32 | 39 |
Basal cell carcinoma | 91.4% | 47 | 304 | 13 | 11 |
Bladder cancer | 78.1% | 29 | 46 | 21 | 19 |
Chronic myeloid leukemia | 55.2% | 73 | 185 | 44 | 47 |
Colorectal cancer | 63.6% | 49 | 104 | 34 | 33 |
Endometrial cancer | 68.6% | 46 | 88 | 24 | 23 |
Glioma | 33.4% | 69 | 209 | 55 | 61 |
Melanoma | 91.2% | 70 | 282 | 22 | 23 |
Nonsmall-cell lung cancer | 18.0% | 73 | 183 | 36 | 43 |
Pancreatic cancer | 5.5% | 67 | 134 | 43 | 43 |
Prostate cancer | 99.4% | 99 | 333 | 40 | 45 |
Renal cell carcinoma | 69.5% | 57 | 104 | 36 | 33 |
Small cell lung cancer | 6.2% | 86 | 238 | 31 | 37 |
Thyroid cancer | 97.2% | 28 | 49 | 18 | 14 |
In addition to the cancer pathways from KEGG, the 5-year survival statistics is collected from the Surveillance Epidemiology and End Results (SEER) Program database (http://seer.cancer.gov/), which is a resource for epidemiological data compiled by the National Cancer Institute as a service to researchers and physicians. Thanks to KEGG and SEER, the connection between cancer network structure and patient survivability can be investigated.
The early research on a category of robustness measures mainly based on connectivity which can be traced back to 1970 [15,3,17]. After that, several analytically studies on network robustness from the viewpoint of random graph theory are proposed [8,9,24]. Taking the critical fraction of attacks and realistic cases, widely used robustness measures based on percolation theory is proposed [23,29,18]. Another remarkable kind of robustness measures are designed based on the eigenvalue of network matrix cite10, 11, 25.
Measures based on connectivity basically consider the connectivity of networks, so it is not interesting now, but the next three categories analyzing the breaking down network, isolating network nodes and redundant circles seem to be useful. So 6 widely used measures, 2 for each category and excavating the different aspect of networks, including robustness
Robustness
(1) |
where
The definition of
(2) |
where
The critical fraction under random attack is marked as
(3) |
where
In [9], the critical fraction under targeted attack
In fact, according to the definition in [9], we can calculate the
Algebraic connectivity is the second smallest eigenvalue of the Laplacian matrix. Fiedler [14] showed that the magnitude of the algebraic connectivity reflects how well connected the overall graph is and Merris in [19] gave a survey of the vast literature on algebraic connectivity.
(4) |
Wu et al. [27] introduce the concept of natural connectivity, which characterizes the redundancy of alternative routes in a network by quantifying the weighed number of closed walks of all lengths. The natural connectivity can be regarded as an average eigenvalue that changes strictly monotonically with the addition or deletion of edges.
(5) |
where
In this section, the relationships between CSNs robustness and 5-year survival rate are reported first, and then interesting CSN-GOs are analyzed in detail. Robustness of CSNs including CSN-EG and CSN-GO related to 5-year survival rate are analyzed according to the Pearson's correlation coefficient which is defined as:
(6) |
where the
In this part, the results of the vector of 14 CSNs, including CSN-EG and CSN-GO, robustness are calculated and the Pearson's correlation coefficient is reported in Table 2.
CSN |
||||||
CSN-EG | 0.31 | 0.28 | -0.11 | 0.34 | 0.049 | 0.24 |
CSN-GO | 0.18 | 0.17 | -0.56 | 0.36 | 0.21 | -0.60 |
From the results, we can find that relationship between robustness and 5-year survival rate are not strongly correlated in group of CSN-EG, while in CSN-GO,
In this part, the degree-entropy
From the table 3, we can see that the natural connectivity is same to the result of degree-entropy
Network parameters | H | Q | λ |
γ | -0.62 | -0.21 | -0.60 |
Next, three of the most effected nodes measured by natural connectivity are obtained through attack. For each attached node, the more affected the natural connectivity is, the more important the node is. After obtaining the top three affected nodes, the degree, closeness centrality and betweenness centrality of these nodes are analyzed. The results are given in Table 4 and Table 5.
Cancer site | Degree | Closeness | Betweenness | |
Acute myeloid leukemia | Top 1 | 6.00 | 14.92 | 545.00 |
Top 2 | 7.00 | 12.55 | 269.83 | |
Top 3 | 5.00 | 14.45 | 500.17 | |
Average | 2.43 | 10.17 | 98.00 | |
Basal cell carcinoma | Top 1 | 5.00 | 6.45 | 60.00 |
Top 2 | 2.00 | 5.28 | 50.00 | |
Top 3 | 2.00 | 4.92 | 48.00 | |
Average | 1.82 | 4.46 | 22.73 | |
Bladder cancer | Top 1 | 3.00 | 5.17 | 38.00 |
Top 2 | 3.00 | 4.83 | 26.00 | |
Top 3 | 3.00 | 4.67 | 26.00 | |
Average | 1.78 | 3.99 | 13.33 | |
Chronic myeloid leukemia | Top 1 | 7.00 | 12.38 | 217.00 |
Top 2 | 5.00 | 12.09 | 303.00 | |
Top 3 | 5.00 | 11.67 | 318.00 | |
Average | 2.15 | 8.44 | 78.85 | |
Colorectal cancer | Top 1 | 5.00 | 8.59 | 188.00 |
Top 2 | 4.00 | 7.71 | 147.00 | |
Top 3 | 4.00 | 8.74 | 274.00 | |
Average | 2.09 | 6.73 | 91.39 | |
Endometrial cancer | Top 1 | 5.00 | 7.30 | 85.00 |
Top 2 | 3.00 | 6.88 | 121.00 | |
Top 3 | 3.00 | 6.88 | 142.00 | |
Average | 2.00 | 5.62 | 57.65 | |
Glioma | Top 1 | 5.00 | 9.70 | 78.00 |
Top 2 | 4.00 | 10.25 | 141.17 | |
Top 3 | 4.00 | 9.15 | 36.17 | |
Average | 2.42 | 7.61 | 36.74 |
Cancer site | Degree | Closeness | Betweenness | |
Melanoma | Top 1 | 3.00 | 6.58 | 73.00 |
Top 2 | 3.00 | 6.50 | 58.00 | |
Top 3 | 3.00 | 6.06 | 43.00 | |
Average | 2.00 | 5.15 | 26.77 | |
Nonsmall-cell lung cancer | Top 1 | 5.00 | 12.45 | 346.73 |
Top 2 | 5.00 | 11.42 | 91.67 | |
Top 3 | 5.00 | 11.42 | 91.67 | |
Average | 2.45 | 9.25 | 110.19 | |
Pancreatic cancer | Top 1 | 5.00 | 6.95 | 45.00 |
Top 2 | 4.00 | 6.78 | 61.00 | |
Top 2 | 3.00 | 5.95 | 7.00 | |
Average | 2.33 | 5.24 | 22.17 | |
Prostate cancer | Top 1 | 12.00 | 18.07 | 850.67 |
Top 2 | 3.00 | 13.16 | 546.00 | |
Top 3 | 4.00 | 8.33 | 93.00 | |
Average | 2.29 | 9.92 | 156.29 | |
Renal cell carcinoma | Top 1 | 5.00 | 9.08 | 160.00 |
Top 2 | 3.00 | 7.20 | 28.00 | |
Top 3 | 3.00 | 7.20 | 28.00 | |
Average | 2.00 | 6.06 | 34.38 | |
Small cell lung cancer | Top 1 | 7.00 | 8.75 | 126.00 |
Top 2 | 3.00 | 5.78 | 67.00 | |
Top 3 | 2.00 | 6.65 | 98.00 | |
Average | 2.00 | 5.65 | 38.80 | |
Thyroid cancer | Top 1 | 3.00 | 4.17 | 18.00 |
Top 2 | 3.00 | 4.17 | 18.00 | |
Top 3 | 2.00 | 4.00 | 18.00 | |
Average | 1.71 | 3.38 | 7.71 |
Table 4 and Table 5 give the degree, closeness centrality and betweenness centrality of the top three effected nodes measured by natural connectivity and the averaged values of the networks. From Table IV, we find only few number of closeness and betweenness lower than the average level. That to say, the nodes found are important and we think that the natural connectivity is suitable for measuring the robustness of CSNs and we believe that these information will be a great help to cancer treatment. The further investigation will be carried on with the cooperation of biologist.
In this paper, a comparative study of robustness measures for CSNs is given by studying six different robustness measures with two kinds of CSNs, i.e. CSN-EG and CSN-GO. CSN-EG and CSN-GO are two kind networks obtained from the same KGML in which the protein, ramification are included or not, respectively. In fact, the CSNs can repair themselves dynamically, so attack on reproducible protein may not mortal to CSNs. For CSN-EG, large numbers of protein are included, so the natural connectivity is affected and lost its works on them. From the study, the
Furthermore, the top three affected nodes measured by natural connectivity are obtained and the degree, closeness centrality and betweenness centrality of these nodes are given. From the results, we find the nodes found according to natural connectivity are important, that is to say the natural connectivity catch the essentials of CSN-GO. Otherwise, the natural connectivity describes the redundancy of routes between vertices which is directly related to the information exchange or communication of CSN.
Through analysis on CSNs in complex network theory method, the conclusion that the natural connectivity is suitable for measuring the robustness of CSNs is obtained, and we believe that this information will be a great help to cancer treatment. The further investigation will be carried on with the cooperation of biologist.
This work is partially supported by the Outstanding Young Scholar Program of National Natural Science Foundation of China (NSFC) under Grant 61522311, the General Program of NSFC under Grant 61773300, the Overseas, Hong Kong & Macao Scholars Collaborated Research Program of NSFC under Grant 61528205, and the Key Program of Fundamental Research Project of Natural Science of Shaanxi Province, China under Grant 2017JZ017..
[1] |
Albert R., Jeong H., Barabási A. -L. (2000) Error and attack tolerance of complex networks. Nature 406: 378-382. doi: 10.1038/35019019
![]() |
[2] |
Andrec M., Kholodenko B. N., Levy R. M., Sontag E. (2005) Inference of signalingand gene regulatory networks by steady-state perturbation experiments: Structure and accuracy. Journal of Theoretical Biology 232: 427-441. doi: 10.1016/j.jtbi.2004.08.022
![]() |
[3] |
D. Bauer, F. Boesch, C. Suffel and R. Tindell, Connectivity extremal problems and the design of reliable probabilistic networks, The Theory and Application of Graphs, Wiley, New York, (1981), 45–54. MR634515 |
[4] |
Bonacich P. (2007) Some unique properties of eigenvector centrality. Social Networks 29: 555-564. doi: 10.1016/j.socnet.2007.04.002
![]() |
[5] | Brandes U. (2008) On variants of shortest-path betweenness centrality and their generic computation. Social Networks 30: 136-145. |
[6] | Breitkreutz D., Hlatky L., Rietman E., Tuszynski J. A. (2012) Molecular signalingnetwork complexity is correlated with cancer patient survivability. Proceedings of the National Academy of Sciences 109: 9209-9212. |
[7] |
Callaway D. S., Newman M. E. J., Strogatz S. H., Watts D. J. (2000) Network robustness and fragility: Percolation on random graphs. Physical Review L 85: 5468-5471. doi: 10.1103/PhysRevLett.85.5468
![]() |
[8] |
Cohen R., Erez K., Ben-Avraham D., Havlin S. (2000) Resilience of the Internet to random breakdowns. Physical Review L 85: 4626-4628. doi: 10.1103/PhysRevLett.85.4626
![]() |
[9] |
Cohen R., Erez K., Ben-Avraham D., Havlin S. (2001) Breakdown of the Internet under intentional attack. Physical Review L 86: 3682-3685. doi: 10.1103/PhysRevLett.86.3682
![]() |
[10] |
Dong C., Hemminki K. (2001) Multiple primary cancers of the colon, breast and skin (melanoma) as models for polygenic cancers. International Journal of Cancer 92: 883-887. doi: 10.1002/ijc.1261
![]() |
[11] |
Edelman E. J., Guinney J., Chi J.-T., Febbo P. G., Mukherjee S. (2008) Modeling cancer progression via pathway dependencies. PLoS Comput Biol 4: e28. doi: 10.1371/journal.pcbi.0040028
![]() |
[12] | Estrada E., Higham D. J., Hatano N. (2009) Communicability betweenness in 315 complex networks. Physica A: Statistical Mechanics and its Applications 388: 764-774. |
[13] |
Feala J. D., Cortes J., Duxbury P. M., Piermarocchi C., McCulloch A. D., Paternostro G. (2010) Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 2: 181-193. doi: 10.1002/wsbm.51
![]() |
[14] | Fiedler M. (1973) Algebraic connectivity of graphs. Czechoslovak Mathematical Journal 23: 298-305. |
[15] | Frank H., Frisch I. T. (1970) Analysis and design of survivable networks. IEEE Transactions on Communication Technology 18: 501-519. |
[16] |
Hage P., Harary F. (1995) Eccentricity and centrality in networks. Social Networks 17: 57-63. doi: 10.1016/0378-8733(94)00248-9
![]() |
[17] |
Harary F. (1983) Conditional connectivity. Networks 13: 347-357. doi: 10.1002/net.3230130303
![]() |
[18] |
Louzada V. H., Daolio F., Herrmann H. J., Tomassini M. (2015) Generating robust and efficient networks under targeted attacks. Propagation Phenomena in Real World Networks 85: 215-244. doi: 10.1007/978-3-319-15916-4_9
![]() |
[19] |
Merris R. (1994) Laplacian matrices of graphs: A survey. Linear Algebra and its Applications 197: 143-176. doi: 10.1016/0024-3795(94)90486-3
![]() |
[20] |
Nacher J. C., Schwartz J.-M. (2008) A global view of drug-therapy interactions. BMC pharmacology 8: 5pp. doi: 10.1186/1471-2210-8-5
![]() |
[21] |
Paul G., Sreenivasan S., Stanley H. E. (2005) Resilience of complex networks to random breakdown. Physical Review E 72: 056130, 6pp. doi: 10.1103/PhysRevE.72.056130
![]() |
[22] |
Penfold C. A., Buchanan-Wollaston V., Denby K. J., Wild D. L. (2012) Nonparametric bayesian inference for perturbed and orthologous gene regulatory networks. Bioinformatics 28: i233-i241. doi: 10.1093/bioinformatics/bts222
![]() |
[23] |
Schneider C. M., Moreira A. A., Andrade J. S., Havlin S., Herrmann H. J. (2011) Mitigation of malicious attacks on networks. Proc. Natl. Acad. Sci. U.S.A. 108: 3838-3841. doi: 10.1073/pnas.1009440108
![]() |
[24] |
Shargel B., Sayama H., Epstein I. R., Bar-Yam Y. (2003) Optimization of robustness and connectivity in complex networks. Physical Review L 90: 068701. doi: 10.1103/PhysRevLett.90.068701
![]() |
[25] | Sonnenschein C., Soto A. M. (2008) Theories of carcinogenesis: an emerging per-275 spective, in: Seminars in cancer biology. Seminars in Cancer Biology 18: 372-377. |
[26] |
Takemoto K., Kihara K. (2013) Modular organization of cancer signaling networks is associated with patient survivability. Biosystems 113: 149-154. doi: 10.1016/j.biosystems.2013.06.003
![]() |
[27] |
Wu J., Barahona M., Tan Y.-J., Deng H.-Z. (2015) Spectral measure of structural robustness in complex networks. IEEE Transactions on Syst. Man Cybern. A Syst. and Humans 41: 1244-1252. doi: 10.1109/TSMCA.2011.2116117
![]() |
[28] | Yildirim M. A., Goh K.-I., Cusick M. E., Barabási A.-L., Vidal M. (2007) Drug-target network. Nature Biotechnology 25: 1119-1126. |
[29] |
Zeng A., Liu W. (2012) Enhancing network robustness against malicious attacks. Physical Review E 85: 066130. doi: 10.1103/PhysRevE.85.066130
![]() |
Cancer site | 5-y survival probability | CSN-EG | CSN-GO | ||
Nodes | Edges | Nodes | Edges | ||
Acute myeloid leukemia | 23.6% | 57 | 152 | 32 | 39 |
Basal cell carcinoma | 91.4% | 47 | 304 | 13 | 11 |
Bladder cancer | 78.1% | 29 | 46 | 21 | 19 |
Chronic myeloid leukemia | 55.2% | 73 | 185 | 44 | 47 |
Colorectal cancer | 63.6% | 49 | 104 | 34 | 33 |
Endometrial cancer | 68.6% | 46 | 88 | 24 | 23 |
Glioma | 33.4% | 69 | 209 | 55 | 61 |
Melanoma | 91.2% | 70 | 282 | 22 | 23 |
Nonsmall-cell lung cancer | 18.0% | 73 | 183 | 36 | 43 |
Pancreatic cancer | 5.5% | 67 | 134 | 43 | 43 |
Prostate cancer | 99.4% | 99 | 333 | 40 | 45 |
Renal cell carcinoma | 69.5% | 57 | 104 | 36 | 33 |
Small cell lung cancer | 6.2% | 86 | 238 | 31 | 37 |
Thyroid cancer | 97.2% | 28 | 49 | 18 | 14 |
CSN |
||||||
CSN-EG | 0.31 | 0.28 | -0.11 | 0.34 | 0.049 | 0.24 |
CSN-GO | 0.18 | 0.17 | -0.56 | 0.36 | 0.21 | -0.60 |
Network parameters | H | Q | λ |
γ | -0.62 | -0.21 | -0.60 |
Cancer site | Degree | Closeness | Betweenness | |
Acute myeloid leukemia | Top 1 | 6.00 | 14.92 | 545.00 |
Top 2 | 7.00 | 12.55 | 269.83 | |
Top 3 | 5.00 | 14.45 | 500.17 | |
Average | 2.43 | 10.17 | 98.00 | |
Basal cell carcinoma | Top 1 | 5.00 | 6.45 | 60.00 |
Top 2 | 2.00 | 5.28 | 50.00 | |
Top 3 | 2.00 | 4.92 | 48.00 | |
Average | 1.82 | 4.46 | 22.73 | |
Bladder cancer | Top 1 | 3.00 | 5.17 | 38.00 |
Top 2 | 3.00 | 4.83 | 26.00 | |
Top 3 | 3.00 | 4.67 | 26.00 | |
Average | 1.78 | 3.99 | 13.33 | |
Chronic myeloid leukemia | Top 1 | 7.00 | 12.38 | 217.00 |
Top 2 | 5.00 | 12.09 | 303.00 | |
Top 3 | 5.00 | 11.67 | 318.00 | |
Average | 2.15 | 8.44 | 78.85 | |
Colorectal cancer | Top 1 | 5.00 | 8.59 | 188.00 |
Top 2 | 4.00 | 7.71 | 147.00 | |
Top 3 | 4.00 | 8.74 | 274.00 | |
Average | 2.09 | 6.73 | 91.39 | |
Endometrial cancer | Top 1 | 5.00 | 7.30 | 85.00 |
Top 2 | 3.00 | 6.88 | 121.00 | |
Top 3 | 3.00 | 6.88 | 142.00 | |
Average | 2.00 | 5.62 | 57.65 | |
Glioma | Top 1 | 5.00 | 9.70 | 78.00 |
Top 2 | 4.00 | 10.25 | 141.17 | |
Top 3 | 4.00 | 9.15 | 36.17 | |
Average | 2.42 | 7.61 | 36.74 |
Cancer site | Degree | Closeness | Betweenness | |
Melanoma | Top 1 | 3.00 | 6.58 | 73.00 |
Top 2 | 3.00 | 6.50 | 58.00 | |
Top 3 | 3.00 | 6.06 | 43.00 | |
Average | 2.00 | 5.15 | 26.77 | |
Nonsmall-cell lung cancer | Top 1 | 5.00 | 12.45 | 346.73 |
Top 2 | 5.00 | 11.42 | 91.67 | |
Top 3 | 5.00 | 11.42 | 91.67 | |
Average | 2.45 | 9.25 | 110.19 | |
Pancreatic cancer | Top 1 | 5.00 | 6.95 | 45.00 |
Top 2 | 4.00 | 6.78 | 61.00 | |
Top 2 | 3.00 | 5.95 | 7.00 | |
Average | 2.33 | 5.24 | 22.17 | |
Prostate cancer | Top 1 | 12.00 | 18.07 | 850.67 |
Top 2 | 3.00 | 13.16 | 546.00 | |
Top 3 | 4.00 | 8.33 | 93.00 | |
Average | 2.29 | 9.92 | 156.29 | |
Renal cell carcinoma | Top 1 | 5.00 | 9.08 | 160.00 |
Top 2 | 3.00 | 7.20 | 28.00 | |
Top 3 | 3.00 | 7.20 | 28.00 | |
Average | 2.00 | 6.06 | 34.38 | |
Small cell lung cancer | Top 1 | 7.00 | 8.75 | 126.00 |
Top 2 | 3.00 | 5.78 | 67.00 | |
Top 3 | 2.00 | 6.65 | 98.00 | |
Average | 2.00 | 5.65 | 38.80 | |
Thyroid cancer | Top 1 | 3.00 | 4.17 | 18.00 |
Top 2 | 3.00 | 4.17 | 18.00 | |
Top 3 | 2.00 | 4.00 | 18.00 | |
Average | 1.71 | 3.38 | 7.71 |
Cancer site | 5-y survival probability | CSN-EG | CSN-GO | ||
Nodes | Edges | Nodes | Edges | ||
Acute myeloid leukemia | 23.6% | 57 | 152 | 32 | 39 |
Basal cell carcinoma | 91.4% | 47 | 304 | 13 | 11 |
Bladder cancer | 78.1% | 29 | 46 | 21 | 19 |
Chronic myeloid leukemia | 55.2% | 73 | 185 | 44 | 47 |
Colorectal cancer | 63.6% | 49 | 104 | 34 | 33 |
Endometrial cancer | 68.6% | 46 | 88 | 24 | 23 |
Glioma | 33.4% | 69 | 209 | 55 | 61 |
Melanoma | 91.2% | 70 | 282 | 22 | 23 |
Nonsmall-cell lung cancer | 18.0% | 73 | 183 | 36 | 43 |
Pancreatic cancer | 5.5% | 67 | 134 | 43 | 43 |
Prostate cancer | 99.4% | 99 | 333 | 40 | 45 |
Renal cell carcinoma | 69.5% | 57 | 104 | 36 | 33 |
Small cell lung cancer | 6.2% | 86 | 238 | 31 | 37 |
Thyroid cancer | 97.2% | 28 | 49 | 18 | 14 |
CSN |
||||||
CSN-EG | 0.31 | 0.28 | -0.11 | 0.34 | 0.049 | 0.24 |
CSN-GO | 0.18 | 0.17 | -0.56 | 0.36 | 0.21 | -0.60 |
Network parameters | H | Q | λ |
γ | -0.62 | -0.21 | -0.60 |
Cancer site | Degree | Closeness | Betweenness | |
Acute myeloid leukemia | Top 1 | 6.00 | 14.92 | 545.00 |
Top 2 | 7.00 | 12.55 | 269.83 | |
Top 3 | 5.00 | 14.45 | 500.17 | |
Average | 2.43 | 10.17 | 98.00 | |
Basal cell carcinoma | Top 1 | 5.00 | 6.45 | 60.00 |
Top 2 | 2.00 | 5.28 | 50.00 | |
Top 3 | 2.00 | 4.92 | 48.00 | |
Average | 1.82 | 4.46 | 22.73 | |
Bladder cancer | Top 1 | 3.00 | 5.17 | 38.00 |
Top 2 | 3.00 | 4.83 | 26.00 | |
Top 3 | 3.00 | 4.67 | 26.00 | |
Average | 1.78 | 3.99 | 13.33 | |
Chronic myeloid leukemia | Top 1 | 7.00 | 12.38 | 217.00 |
Top 2 | 5.00 | 12.09 | 303.00 | |
Top 3 | 5.00 | 11.67 | 318.00 | |
Average | 2.15 | 8.44 | 78.85 | |
Colorectal cancer | Top 1 | 5.00 | 8.59 | 188.00 |
Top 2 | 4.00 | 7.71 | 147.00 | |
Top 3 | 4.00 | 8.74 | 274.00 | |
Average | 2.09 | 6.73 | 91.39 | |
Endometrial cancer | Top 1 | 5.00 | 7.30 | 85.00 |
Top 2 | 3.00 | 6.88 | 121.00 | |
Top 3 | 3.00 | 6.88 | 142.00 | |
Average | 2.00 | 5.62 | 57.65 | |
Glioma | Top 1 | 5.00 | 9.70 | 78.00 |
Top 2 | 4.00 | 10.25 | 141.17 | |
Top 3 | 4.00 | 9.15 | 36.17 | |
Average | 2.42 | 7.61 | 36.74 |
Cancer site | Degree | Closeness | Betweenness | |
Melanoma | Top 1 | 3.00 | 6.58 | 73.00 |
Top 2 | 3.00 | 6.50 | 58.00 | |
Top 3 | 3.00 | 6.06 | 43.00 | |
Average | 2.00 | 5.15 | 26.77 | |
Nonsmall-cell lung cancer | Top 1 | 5.00 | 12.45 | 346.73 |
Top 2 | 5.00 | 11.42 | 91.67 | |
Top 3 | 5.00 | 11.42 | 91.67 | |
Average | 2.45 | 9.25 | 110.19 | |
Pancreatic cancer | Top 1 | 5.00 | 6.95 | 45.00 |
Top 2 | 4.00 | 6.78 | 61.00 | |
Top 2 | 3.00 | 5.95 | 7.00 | |
Average | 2.33 | 5.24 | 22.17 | |
Prostate cancer | Top 1 | 12.00 | 18.07 | 850.67 |
Top 2 | 3.00 | 13.16 | 546.00 | |
Top 3 | 4.00 | 8.33 | 93.00 | |
Average | 2.29 | 9.92 | 156.29 | |
Renal cell carcinoma | Top 1 | 5.00 | 9.08 | 160.00 |
Top 2 | 3.00 | 7.20 | 28.00 | |
Top 3 | 3.00 | 7.20 | 28.00 | |
Average | 2.00 | 6.06 | 34.38 | |
Small cell lung cancer | Top 1 | 7.00 | 8.75 | 126.00 |
Top 2 | 3.00 | 5.78 | 67.00 | |
Top 3 | 2.00 | 6.65 | 98.00 | |
Average | 2.00 | 5.65 | 38.80 | |
Thyroid cancer | Top 1 | 3.00 | 4.17 | 18.00 |
Top 2 | 3.00 | 4.17 | 18.00 | |
Top 3 | 2.00 | 4.00 | 18.00 | |
Average | 1.71 | 3.38 | 7.71 |